Females of reproductive potential must have negative pregnancy testing and use contraception methods before initiating POMALYST [see WARNINGS AND PRECAUTIONS and Use In Specific Populations].
The recommended starting dose of POMALYST is 4 mg once daily orally on Days 1-21 of repeated28-day cycles until disease progression. POMALYST should be given in combination with dexamethasone [see Clinical Studies].
POMALYST may be taken with water. Inform patients not to break, chew, or open the capsules. POMALYST should be taken without food (at least 2 hours before or 2 hours after a meal).
Table 1: Dose Modification Instructions for POMALYST for Hematologic Toxicities 
To initiate a new cycle of POMALYST, the neutrophil count must be at least 500 per mcL and the platelet count must be at least 50,000 per mcL. If toxicities occur after dose reductions to 1 mg, then discontinue POMALYST.
Permanently discontinue POMALYST for angioedema, skin exfoliation, bullae, or any other severe dermatologic reaction [see WARNINGS AND PRECAUTIONS].
For other Grade 3 or 4 toxicities, hold treatment and restart treatment at 1 mg less than the previous dose when toxicity has resolved to less than or equal to Grade 2 at the physician's discretion.
Avoid co-administration of strong inhibitors of CYP1A2. If necessary to co-administer strong inhibitors of CYP1A2 in the presence of strong inhibitors of CYP3A4 and P-gp, reduce POMALYST dose by 50%. No clinical efficacy or safety data exist [see DRUG INTERACTIONS and CLINICAL PHARMACOLOGY].
